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STABLE ANGINA
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OBJECTIVE: The aim of this study was to explore cost and
health consequences of using drug eluting stents (DES) instead
of bare metal stents (BMS) for patients with stable angina.
METHODS: We developed a Markov model which captures
costs and outcomes the ﬁrst two years after PCI with stent for
stable angina. After each PCI, patients can become well, have a
new intervention (PCI og CABG) or die. The model was based
on meta-analyses of trials comparing DES with BMS. These trials
indicate that the use of DES reduces the need for repeat revas-
cularisation by 36% to 86%. We assumed that DES will reduce
mortality because of fewer intervention related deaths, but also
explored a potential increased mortality because the meta-
analysis indicates a non-signiﬁcant trend towards increased 
mortality of DES compared to BMS. One-way and Monte-Carlo
sensitivity analyses were applied. RESULTS: The estimated cost
per avoided reintervention was $5000 when BMS was replaced
by DES, ranging from $200 to $16,000 in one-way sensitivity
analyses. The price of a drug eluting stent would have to be
reduced from currently $2000 to $1400 to make the use of DES
cost saving compared to BMS (current purchasing price $560).
The estimated cost per life year gained and quality adjusted life
year gained were $121,000 and $46,000, respectively, when
increased mortality was disregarded in the model. Probabilistic
sensitivity analysis indicated a 64% probability that drug eluting
stents were cost-effective if society is willing to pay $50,000 for
one quality adjusted life year. When the increased mortality was
included, BMS was the dominant strategy, with both lower costs
and greater life expectancy. CONCLUSIONS: The cost-
effectiveness of DES depended heavily on purchasing price of the
stents and rate of reintervention in routine practice and may not
be cost-effective at current price level.
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OBJECTIVES: To examine if intensive statin therapy beneﬁts
demonstrated in randomized clinical trials (RCTs) could be sub-
stantiated in managed care patients hospitalized for cardiovas-
cular events and procedures (CVEP). METHODS: An integrated
US medical/pharmacy claims database (43 million members) was
used to examine patient mortality risk following hospitalization
discharge for CVEP (nonfatal MI, resuscitated cardiac arrest,
acute coronary occlusion, CABG or PTCA). Inclusion criteria:
age 18 years, health plan enrollment >12 months prior to and
>1 month after hospitalization, and index hospitalization for
CVEP between January 2000 to June 2003. Patients were iden-
tiﬁed as receiving no statin therapy within 30 days after dis-
charge (S-), or receiving statin therapy. Statin therapy was
deﬁned as standard (STD) or intensive (INT), < or >40% LDL-
C lowering efﬁcacy according to the package insert. Patients
were matched (INT vs. S-, STD vs. S-, and INT vs. STD) based
on estimated propensity scores for statin therapy to adjust for
baseline differences. Death was presumed from claims activity
indicating a likely fatal event followed by health plan disenroll-
ment. Mortality was compared among groups using Cox pro-
portional hazards models controlling for prognostic factors.
RESULTS: Among matched pairs, crude death rates were 
3.26% vs. 5.21% for INT vs. S- (n = 1688 matched pairs);
4.39% vs. 5.75% for STD vs. S- (n = 2346 matched pairs); and
2.33% vs. 3.26% for INT vs. STD (n = 3342 matched pairs). In
Cox Proportional hazards models, risk of death was lower
among patients treated with INT and STD therapy vs. S- (INT
vs. S- Hazard Ratio [HR] = 0.581, 95% CI = 0.414, 0.816, p =
0.0017; STD vs. S- HR = 0.677, 95% CI = 0.525, 0.872, p =
0.0026). Patients receiving INT had 30% lower risk of death
compared to STD (HR = 0.707, 95% CI = 0.528, 0.947; p =
0.0200). CONCLUSIONS: This real-world study validates ben-
eﬁts of intensive statin therapy reported in recent RCTs, and 
clinically signiﬁcant reductions in mortality following cardio-
vascular hospitalization.
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OBJECTIVES: Arrhythmogenic right ventricular cardiomyopa-
thy (ARVC) is a genetically determined heart muscle disease
associated with arrhythmia, heart failure and sudden death often
being the ﬁrst manifestation in probands. The aim of the study
was to evaluate the costs of diagnosis of the disease in asymp-
tomatic relatives in Poland. METHODS: A total of 239 asymp-
tomatic subjects (mean age 35 yeas, 120 men) belonging to 42
families affected with ARVC were examined between May 2003
and May 2005. The costs of out-patients visit and additional
diagnostic tests were included. Payer perspective was used.
RESULTS: In all individuals electrocardiogram and transthoracic
echocardiography were performed. Magnetic resonance imaging
and signal averaged electrocardiogram were performed in 35
patients suspected of having ARVC. The diagnostic criteria for
ARVC were detected in 29 patients and 57 subjects fulﬁlled the
borderline criteria for ARVC. Total costs of screening amounted
to €13,086.35. The average cost per one case of ARVC detected
was €451.25. CONCLUSIONS: Costs of early detection of
ARVC in individuals with a family history of the disease are low
and enable the family screening in asymptomatic subjects in
Poland.
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OBJECTIVES: Arrhythmogenic right ventricular cardiomyopa-
thy (ARVC) is a progressive heart muscle disease characterized
by replacement of right ventricular myocardium by ﬁbrofatty
tissue and resulting in life threatening ventricular arrhythmias
and heart failure. The aim of the study was to evaluate costs of
hospital care in cardiology department for patients with ARVC
in Poland. METHODS: Data on resource utilization were col-
lected prospectively in patients with ARVC hospitalized in the
tertiary center from May 2003 to May 2005. Patients’ stay ﬁxed
costs, costs of additional tests and procedures were extracted
from hospital sources. Payer perspective was used. RESULTS: A
group of 39 patients with mean age 41.4 years (56% male) was
analyzed. Average length of stay in the cardiologic department
was 13.4 days (ranging from 2 to 76 days). Total costs of hos-
pital care amounted to €191,029.90. Average cost per patient
was €4898.20. Procedural costs represented the major cost item
